Abstract

Background: We aimed to investigate the role of HIF-2α on chronic allograft nephropathy, which is a consequence of chronic inflammation and fibrosis.
Method: The study was conducted between November 2019 and January 2021, patients who had a kidney biopsy in our university in the last two years were included in the study. 15 patients with a diagnosis of chronic allograft nephropathy proven by biopsy, 15 patients with an eGFR below 60 ml/dk for other reasons as non-CAN group. Also, 15 patients with an eGFR above 60 ml/dk were included in the study as a control group. Serum HIF-2α levels were detected by a commercial kit using the quantitative sandwich enzyme immunoassay technique.
Results: HIF-2α was higher in the CAN group compared to other groups. HIF-2α was significantly predictive in ROC analysis in identifying renal transplantation patients with CAN. The sensitivity and specificity of HIF-2α were 100% and 76% (cut off >0.2) with an area of under the ROC curve of 0.941 (95% CI 0. 850-1.000), p < 0.001).
Conclusion: Serum HIF-2α may usefulness as potential simple biomarkers for detecting allograft dysfunction after kidney transplantation and it can be also a guide in determining these treatment strategies.

Key words: chronic allograft nephropathy;renal transplantation HIF-2α